Finance

Over two years into a bear market, it still can’t catch a sustainable bid.

Experts from Kallyope share biotech challenges they have faced and overcome as well as ways to go about securing funds in this exclusive Q&A.

Looking at corporate value through a portfolio lens provides an astute and reliable path to genuine value creation.

While industry financial markets continued to experience subdued dollar volumes in 2022, dealmaking held steady—with factors such as pharma pursuing strategic priorities and biotech funding woes playing major roles.

Is stock market outperformance for biotech still in the cards for 2023?

According to the 2023 State of Revenue Report, pharma companies are prioritizing digital transformation while struggling with inflation and supply chain disruptions.

Chronicling the market’s rise and fall—and signs of potential recovery.

What a changing economy and related trends could mean for 2023.

Will biopharma investment heat up and signal better fortunes for 2023?

Focus is on cash: who’s got it, who doesn’t, and what will it mean?

Big pharma’s finicky appetite for M&A comes as valuations of sellers soften. Though the pace of deals has picked up some, predicting just how long both sides will hold tight remains difficult.

As fundamentals improve, potential rate plateau could ignite growth.

Rotz discusses a report he co-authored for PwC about how life sciences companies perform on the S&P 500.

Our latest metrics tally across seven business-key measures uncovers some familiar players pacing the field in delivering shareholder value and getting the most from their investments.

Biotech stocks and the indexes have staged an impressive recovery.

Barnes discusses alternative reimbursement plans for expensive, one-off therapies.

A review of pharma and biotech equity market, IPO, and M&A trends and outputs through the first half of 2022—and implications for the future as disruptions continue to have an impact.

A look at the driving factors behind renewed optimism.

A recent analysis of the biotech market shows promising signs.

Kobel discusses taking a company public during a challenging time in the market.

COVID-19 pandemic, the challenging capital-markets climate in biotech, and a more innovative and specialty treatment focus has increased reliance on the finance arm as a key strategic cog.

A summary of key takeaways from EY’s new Beyond Borders report.

Restructuring and ensuring the right talent is in place can help life sciences industry push through latest downward spiral.

Some observations point to hope for an upturn.

Living to fight another day, as potential investment spark looms.